TNFRSF11B and breast carcinoma: The effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in a mouse model of osteolytic breast cancer has clearly indicated the potential of rAAV-OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage [101].